Global Vitiligo
Drugs Market, by Drug Class (Calcineurin Inhibitors, Corticosteroids, and
Psoralens), by Type (Segmental and Non-segmental), by Route of Administration
(Oral and Topical), by Distribution Channel (Hospital Pharmacies, Retail
Pharmacies, and Online Pharmacies), and by Region (North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$
120.6 million in 2017, and is projected to exhibit a CAGR of 8.4% over the
forecast period (2018–2026).
Increasing demand for drugs for
efficient treatment of vitiligo is expected to drive growth of the global
vitiligo drugs market during the forecast period. Research institutes and
manufacturers are focused on research and development of new drugs for the
treatment of vitiligo in order to cater to increasing consumer demand. For
instance, in June 2019, Incyte Corporation announced positive results from the
phase 2 study of the Ruxolitinib cream, which is a non-steroidal,
anti-inflammatory, JAK inhibitor therapy for patients with vitiligo. Similarly,
in July 2019, the Defense Research and Development Organization (DRDO), India,
announced a research for the development of a new herbal drug for the treatment
of vitiligo. Furthermore, in 2018, Boston Pharmaceutical expanded its product
pipeline by adding a topical formulation called GSK3183475 from GlaksoSmith Kline,
a small molecule inhibitor used in the treatment of vitiligo and psoriasis,
currently in phase 1 clinical trial. Therefore, increasing research and
development activities related to vitiligo drugs is expected to facilitate
growth of the market over the forecast period.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2447
Browse 45 Market Data Tables and
38 Figures spread through 164 Pages and in-depth TOC on “Vitiligo Drugs
Market”- Global Forecast to 2026 by Drug Class (Calcineurin Inhibitors, Corticosteroids,
and Psoralens), by Type (Segmental and Non-segmental), by Route of
Administration (Oral and Topical), by Distribution Channel (Hospital
Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa).
Key players in the market are
focused on adopting collaboration and acquisition strategies to develop and
commercialize novel vitiligo treatment drugs in order to expand their product
portfolio. This in turn is expected to create conducive environment for growth
of the market over the forecast period. For instance, in October 2018, Boston
Pharmaceutical entered into a licensing agreement with GlaxoSmithKline for the
development and commercialization of phase 1 drug products for the treatment of
vitiligo. Similarly, in December 2018, Incyte Corporation and Innovent
Biologics, Inc. entered into a strategic licensing agreement for three clinical
stage products in China. The product includes itacitinib (JAK1 inhibitor) in
phase 2 clinical trials.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/vitiligo-drugs-market-2447
Key Takeaways of the Global
Vitiligo Drugs Market:
The global vitiligo drugs market
is expected to exhibit a CAGR of 8.4% over the forecast period, owing to
factors such as increasing incidence of vitiligo and various government
initiatives to support the treatment of the disease
Among drug class, corticosteroids
segment accounted for a major market share in 2018, as topical corticosteroids
are first-choice of treatment against vitiligo
Among route of administration,
topical segment accounted for a major market share in 2018, owing to the launch
and approval of novel topical medications for the management and treatment of
vitiligo. For instance, in 2014, Dr. Reddy's Laboratories, a pharmaceutical
company based in India, launched the Melgain lotion indicated for the treatment
of vitiligo and other skin pigmentation disorders in India.
Major players operating in the
global vitiligo drugs market include, Dermavant Sciences, Inc., Incyte
Corporation, Aclaris Therapeutics, Inc., Dr. Reddy’s Laboratories Ltd., Bristol
- Myers Squibb, Pfizer, Inc., Clinuvel Pharmaceuticals Ltd., Applied Biology,
Inc., and Boston Pharmaceuticals
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2447
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment